XOMA Royalty (NASDAQ:XOMA) Stock Price Passes Above 200 Day Moving Average – Here’s Why

XOMA Royalty Corporation (NASDAQ:XOMA) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $29.74 and traded as high as $34.71. XOMA Royalty shares last traded at $34.07, with a volume of 44,912 shares traded.

Analyst Upgrades and Downgrades

XOMA has been the subject of several research reports. Wall Street Zen raised XOMA Royalty from a “hold” rating to a “buy” rating in a research report on Monday, August 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of XOMA Royalty in a research note on Wednesday, October 8th. Finally, Zacks Research lowered shares of XOMA Royalty from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 20th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $69.50.

XOMA Royalty Stock Performance

The company has a quick ratio of 4.88, a current ratio of 4.88 and a debt-to-equity ratio of 1.41. The stock has a market capitalization of $401.20 million, a price-to-earnings ratio of -21.41 and a beta of 1.12. The stock’s 50-day simple moving average is $35.93 and its 200 day simple moving average is $29.86.

XOMA Royalty (NASDAQ:XOMA) last posted its quarterly earnings data on Wednesday, August 13th. The biotechnology company reported $0.48 earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.60. The company had revenue of $13.13 million during the quarter, compared to analyst estimates of $9.39 million. XOMA Royalty had a negative net margin of 27.57% and a positive return on equity of 2.63%. Analysts expect that XOMA Royalty Corporation will post -1.41 earnings per share for the current fiscal year.

Insider Transactions at XOMA Royalty

In other XOMA Royalty news, CFO Thomas M. Burns sold 4,330 shares of the business’s stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $35.99, for a total value of $155,836.70. Following the transaction, the chief financial officer owned 30,079 shares of the company’s stock, valued at approximately $1,082,543.21. The trade was a 12.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 9.10% of the company’s stock.

Hedge Funds Weigh In On XOMA Royalty

Several large investors have recently made changes to their positions in the company. Nuveen LLC bought a new stake in XOMA Royalty during the 1st quarter worth about $286,000. Stonepine Capital Management LLC grew its position in shares of XOMA Royalty by 3.3% during the 1st quarter. Stonepine Capital Management LLC now owns 129,813 shares of the biotechnology company’s stock worth $2,587,000 after buying an additional 4,113 shares during the period. CM Management LLC grew its position in shares of XOMA Royalty by 16.4% during the 1st quarter. CM Management LLC now owns 64,000 shares of the biotechnology company’s stock worth $1,276,000 after buying an additional 9,000 shares during the period. Deutsche Bank AG raised its stake in shares of XOMA Royalty by 5,087.9% during the first quarter. Deutsche Bank AG now owns 6,433 shares of the biotechnology company’s stock worth $128,000 after buying an additional 6,309 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in XOMA Royalty in the second quarter valued at approximately $116,000. Institutional investors and hedge funds own 95.92% of the company’s stock.

About XOMA Royalty

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.